Vertex to seek US approval after promising late-stage results for kidney drug

By Kamal Choudhury March 9 (Reuters) - Vertex Pharmaceuticals said on Monday that its experimental drug sharply reduced a key ...
BioPharma Dive

Vertex kidney disease drug hits mark in late-stage study

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...
Seeking Alpha

Vertex Report: U.S. Sees Record-Level Growth in Sales Tax Rates and Rules Changes in 2025 Amid Fiscal Uncertainty

KING OF PRUSSIA, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (VERX) (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 ...

Vertex passes key test in quest to treat kidney diseases

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
Seeking Alpha

Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...
Morningstar

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

This press release contains forward-looking statements that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be ...